BioPhorum response to British Pharmacopoeia ATMP working party draft Part 1 guidance; ‘Characterisation of the Particle Population in AAV Products’.
High Level Analytics
Viewing related articles
Sampling strategy to test for presence of mycoplasma in cell therapies
Oct 2022 | Benchmarking, Cell & Gene Therapy, Deliverable, Deliverables Report, High Level Analytics
BioPhorum member only benchmarking exercise seeking member experience on expectations for mycoplasma testing of cell therapies.
Empty/full Capsids (AAV / LVV) testing strategies
Oct 2022 | Benchmarking, Cell & Gene Therapy, Deliverable, Deliverables Report, High Level Analytics
BioPhorum member benchmarking survey on testing strategies for AAV and LVV empty, full and partially filled capsids.
Approaches to testing allogeneic cell therapies for adventitious viral contaminants
Oct 2022 | Benchmarking, Cell & Gene Therapy, Deliverable, Deliverables Report, High Level Analytics
A BioPhorum member survey examining approaches to testing allogenic cell therapies for adventitious viral contaminants.
High Level Analytics workstream rcAAV testing strategies survey
Jan 2022 | Benchmarking, Cell & Gene Therapy, Deliverable, Deliverables Report, High Level Analytics
A member only survey to benchmark industry experience with replication competent AAV testing. The outcome of the survey will help stimulate further discussion of the topic within the workstream.
Feedback to MHRA / British Pharmacopoeia: Guidance on the application of vector copy number for the cell and gene therapy community​
Oct 2021 | Cell & Gene Therapy, Feedback to agency, High Level Analytics
A BioPhorum member only summary document detailing consolidated feedback and suggested recommendations from the High-Level Analytics team on MHRA / British Pharmacopoeia: Guidance on the application of vector copy number for the cell and gene therapy community​.
Feedback to MHRA / British Pharmacopoeia: Guidance on the application of flow cytometry for the cell and gene therapy community​
Oct 2021 | Cell & Gene Therapy, Feedback to agency, High Level Analytics
Summary of member feedback and recommendations on British Pharmacopoeia: Guidance on the application of flow cytometry for the cell and gene therapy community. A member only document.
Challenges for potency assay development for in vivo and ex vivo gene therapies and the matrix approach
Sep 2021 | Cell & Gene Therapy, High Level Analytics, POI - Cell and Gene Therapy, Publication, Regulatory Strategy
This paper highlights some of the challenges to develop potency assays for gene therapies and promotes a potential solution. It seeks to establish Industry alignment on the benefits of a matrix approach and provides high level guidance on how to adopt this strategy towards potency assay development and validation with examples for in vivo and ex vivo GT processes.